Cancer is daunting in the breadth and scope of its diversity, spanning genetics, cell and tissue biology, pathology, and response to therapy. A high level of complexity in cancer biology is related to the aberrations diversity of cancer cells that are the result of tissue-specific barriers circumvented during tumorigenesis.
Hormone-dependent cancers, which include breast, ovarian, uterine, and prostate cancers contribute to the majority of cancer incidences and deaths worldwide. Among the hormone-dependent cancer hallmarks, sustained proliferative signaling, resisting cell death, and invasion/metastasis activation, are often related to abnormal activation of growth factor/hormone receptors and their signaling pathways.
In the last few decades, considerable efforts have been made to discover new biomarkers and therapeutic options to fight hormone-dependent cancer. Although advances in early diagnosis and detection have been obtained, numerous late diagnoses occur. Moreover, the therapies currently available often fail and patients develop drug resistance and metastasis, and relapse is frequently observed. Consequently, novel attempts are needed to discover novel diagnostic and prognostic biomarkers, identify new therapeutic targets, and design innovative drugs for hormone-dependent cancer management.
This Research Topic aims to cover recent advances in hormone-dependent cancers and more specifically in the detection of new diagnostic and prognostic biomarkers, the therapeutic efficacy of molecular-targeted drugs and novel therapeutic approaches for cancer management.
Potential topics include but are not limited to the following:
- Novel diagnostic and prognostic biomarkers in hormone-dependent cancers;
- New molecular targets for hormone-dependent cancers treatment;
- Novel pharmacological approaches in hormone-dependent cancers therapy.
Cancer is daunting in the breadth and scope of its diversity, spanning genetics, cell and tissue biology, pathology, and response to therapy. A high level of complexity in cancer biology is related to the aberrations diversity of cancer cells that are the result of tissue-specific barriers circumvented during tumorigenesis.
Hormone-dependent cancers, which include breast, ovarian, uterine, and prostate cancers contribute to the majority of cancer incidences and deaths worldwide. Among the hormone-dependent cancer hallmarks, sustained proliferative signaling, resisting cell death, and invasion/metastasis activation, are often related to abnormal activation of growth factor/hormone receptors and their signaling pathways.
In the last few decades, considerable efforts have been made to discover new biomarkers and therapeutic options to fight hormone-dependent cancer. Although advances in early diagnosis and detection have been obtained, numerous late diagnoses occur. Moreover, the therapies currently available often fail and patients develop drug resistance and metastasis, and relapse is frequently observed. Consequently, novel attempts are needed to discover novel diagnostic and prognostic biomarkers, identify new therapeutic targets, and design innovative drugs for hormone-dependent cancer management.
This Research Topic aims to cover recent advances in hormone-dependent cancers and more specifically in the detection of new diagnostic and prognostic biomarkers, the therapeutic efficacy of molecular-targeted drugs and novel therapeutic approaches for cancer management.
Potential topics include but are not limited to the following:
- Novel diagnostic and prognostic biomarkers in hormone-dependent cancers;
- New molecular targets for hormone-dependent cancers treatment;
- Novel pharmacological approaches in hormone-dependent cancers therapy.
